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Key Points
• PET-CT is the modern
standard for staging Hodgkin
lymphoma and can replace
contrast enhanced CT in the
vast majority of cases.
• Agreement between expert
and local readers is sufficient
for the Deauville criteria to
assess response in clinical
trials and the community.
International guidelines recommend that positron emission tomography-computed
tomography (PET-CT) should replace CT in Hodgkin lymphoma (HL). The aims of this
study were to compare PET-CT with CT for staging and measure agreement between
expert and local readers, using a 5-point scale (Deauville criteria), to adapt treatment in a
clinical trial: Response-Adapted Therapy in Advanced Hodgkin Lymphoma (RATHL).
Patients were staged using clinical assessment, CT, and bone marrow biopsy (RATHL
stage). PET-CTwasperformedat baseline (PET0) and after 2 chemotherapy cycles (PET2)
in a response-adapteddesign.PET-CTwas reportedcentrallybyexpertsat 5national core
laboratories. Local readersoptionally scoredPET2scans. TheRATHLandPET-CTstages
were compared. Agreement among experts and between expert and local readers was
measured. RATHL and PET0 stage were concordant in 938 (80%) patients. PET-CT
upstaged159 (14%) anddownstaged74 (6%)patients.Upstagingbyextranodal disease in
bone marrow (92), lung (11), or multiple sites (12) on PET-CT accounted for most
discrepancies. Follow-up of discrepant findings confirmed the PET characterization of
lesions in the vastmajority. Five patientswere upstagedbymarrowbiopsy and 7 by contrast-enhancedCT in the bowel and/or liver or
spleen. PET2 agreement among experts (140 scans) with a k (95% confidence interval) of 0.84 (0.76-0.91) was very good and between
experts and local readers (300 scans) at 0.77 (0.68-0.86) was good. These results confirm PET-CT as themodern standard for staging
HL and that response assessment using Deauville criteria is robust, enabling translation of RATHL results into clinical practice.
(Blood. 2016;127(12):1531-1538)
Introduction
Positron emission tomography (PET) and PET-computed tomography
(CT), using 2-deoxy-2-[18F]ﬂuoro-D-glucose (FDG), has been exten-
sively used for imaging patients with Hodgkin lymphoma (HL).1-5
International guidelines recently recommended that PET-CT be
used for routine staging of FDG-avid lymphomas and for response
assessment using a 5-point scale (5-PS), the so-called Deauville
criteria.6,7
PET-CT was preferred for staging due to improved accuracy
compared with CT and as a baseline for subsequent response
assessment.6 Contrast enhancedCT (ceCT)may be required if accurate
nodal measurement is needed (eg, in clinical trials, assessment of
bowel involvement, compression/thrombosis of central vessels,
and for radiation planning).7 Direct comparison between ceCT
and PET-CT when the CT component is performed as a low-dose
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unenhanced scan suggests that higher dose ceCT has no impact on
lymphoma management.8,9 Further, changes in FDG uptake are
more relevant than changes in nodal size for response assessment.6
Despite this, both ceCT and PET-CT are frequently performed at
diagnosis, with added cost and radiation exposure.
PET is reported to alter stage compared with CT,3,10 but most
publications are retrospective and used stand-alone PET.11-16 Previous
publications compared imaging techniques but do not report the impact
of imaging on the more relevant ﬁnal clinical stage, inclusive of bone
marrow biopsy, and some publications included patients with HL and
non-Hodgkin lymphoma (NHL).17-21
Response assessment with the 5-PS has been reported by a number
of investigators tohavegood interobserver agreement in a training set of
50 patients,22 in a study of 260 advancedHL patients with international
expert readers,23 and in pediatric HL.24 The 5-PS also improves the
positive predictive value of PET compared with previous International
Harmonization Criteria.25 These studies, however, were all retrospec-
tive, and the 5-PS was not used to direct therapy.
The aimsof this studywere todetermine, in a large cohort of patients
with advanced HL, within a prospectively acquired clinical trial, the
difference in staging when unenhanced PET-CT is used in place of
standard assessmentwith clinical examination, ceCT, andbonemarrow
biopsy and the agreement among experts and between experts and local
readers using the 5-PS to adapt treatment in real time.
Methods
Patientswere registered in theResponseAdaptedTherapy inAdvancedHodgkin
Lymphoma (RATHL) study and gave written informed consent in accordance
with the Declaration of Helsinki. The study had Human Ethics Committee
approval in all participating countries.
Staging
Patients underwent clinical assessment and ceCT of the neck, thorax, abdomen,
pelvis, and bone marrow biopsy to assess stage. RATHL included patients with
stages IIB to IV and stage IIA with adverse features. Patients also underwent
a PET-CT scan with low-dose unenhanced CT at staging (PET0). ceCT and
PET-CT scans were performed within 28 days of enrollment. PET-CT scans
were acquired around 60 minutes after the intravenous injection of 350 to
550 MBq FDG. The ceCT scans at diagnosis were reported by the radiologist
Figure 1. Consort flow diagram demonstrating
progress of patients through the trial from baseline
to PET3.
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at the recruiting center, and clinical assessment, CT ﬁndings, and bone marrow
biopsywere used to assign theﬁnal RATHL stage by the treating clinician on the
case report form. In individual cases, ultrasound or magnetic resonance imaging
was also used for staging. Inclusion in the study was based on the RATHL stage
and not PET-CT. The PET-CT stage was assigned by central readers at core labs
in the United Kingdom, Italy, Sweden, Denmark, and Australia without
knowledge of RATHL stage, marrow biopsy, or patient outcome. Causes for
discrepancy in stage between PET-CT and other modalities were assessed with
reference to the imaging reports, bone marrow biopsy results, and by observing
the changes that occurred with treatment on PET scans performed during
chemotherapy. ceCT scans were not re-reviewed centrally. PET-CT scans were
performed at multiple international centers using standardized methods for
acquisition and quality control.26
Response assessment
PET-CT was repeated after 2 cycles of doxorubicin, bleomycin, vinblas-
tine, dacarbazine (ABVD) chemotherapy (PET2). All scans were PET-CT,
and stand-alone PET scans were not permitted in the trial. PET2 scans were
performed 9 to 13 days after day 15 of cycle 2.
PET2 was scored using the 5-PS,6 according to the level of the most intense
residual FDG uptake at involved sites on PET0 as follows: (1) no uptake; (2)
uptake #mediastinum; (3) uptake .mediastinum but #liver; (4) uptake
moderately higher than liver; and (5) uptake markedly higher than liver and/or
new lesions. The term “X” was applied to new areas of uptake unlikely to be
related to lymphoma.
Scores 1, 2, and 3 were regarded as negative, and scores 4 and 5 were
regarded as positive. Score 5 was regarded as uptake $3 times the maximum
standardized uptake value in normal liver.
Patients with negative PET2 were randomized to continue with 4 cycles of
ABVD or have de-escalation of treatment with 4 cycles of AVD (doxorubicin,
vinblastine, dacarbazine). Patients with positive PET2 had escalated treatment
with bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, pro-
carbazine, and prednisone (BEACOPP)-escalated or BEACOPP-14, according
to the treating center preference. A third PET-CT (PET3) was performed 9 to 13
days after day 8 of cycle 3 of BEACOPP-escalated or 2 to 6 days after day 8 of
cycle 4 of BEACOPP-14 to ensure effectiveness of therapy. It was left to the
treating physician’s discretion whether patients were offered salvage therapy if
PET3 remained positive. An end-of-treatment PET scan was not mandated.
Patients with a negative PET2 or PET3 scan were not recommended to receive
consolidation radiotherapy as routine, although local investigators had the
discretion to use radiotherapy if they felt it necessary.
PET2 was scored at the core laboratories within 72 hours, and this score
was used to direct treatment. To assess the level of agreement, readers from
all core laboratories read the same paired PET0 and PET2 scans from (1)
a training set of 50 patients,22 (2) the ﬁrst 10 patients scored at each
core laboratory, and (3) a further 10 patients scored at each core labora-
tory during the trial. Readers at local PET centers were given the option to
score scans. Levels of agreement were measured between central (core
laboratory) readers and between local and central readers, using non-
weighted k statistics27 (Stata version 12.1; Stata Corp). Using this
threshold, uptake in lesions higher than normal liver uptake resulted in
treatment escalation. Agreement was also measured regarding scores 1 and
2 as negative and scores 3 to 5 as positive, as this threshold has been used as
a benchmark for de-escalation in trials involving patients with HL.1,28,29
k values between 0.81 and 1.00 indicate very good agreement, 0.61 and
0.80 indicate good agreement, 0.41 and 0.60 indicate moderate agreement, and
0.21 to 0.4 indicate fair agreement.30
Results
Staging
A total of 1214 patients were registered from 2008 to 2012; 1171
baseline PET-CT scans were available for staging assessment, which
was performed retrospectively (Figure 1).
There was agreement between the RATHL stage and the PET-CT
stage in 938 (80%) patients. A total of 159 patients (14%) were
upstaged and 74 patients (6%)were downstaged by PET-CT (Table 1).
The main reason for upstaging was detection of extranodal disease
(Table 2),most commonly in bonemarrow (Figure 2).Upstaging due to
Table 1. Level of agreement between RATHL stage (assigned by
clinical assessment, ceCT, and bone marrow biopsy) and the
baseline PET-CT
PET-CT
RATHL stage
1 2 3 4
1 0 1 2 0
2 0 406 37 19
3 0 38 240 15
4 0 47 74 292
Table 2. Reasons for upstaging and downstaging according to
PET-CT compared with the RATHL stage
Upstaging by PET-CT due to N (% of upstaged patients)
Extranodal disease on PET-CT in the
following sites
118 (74.2)
Bone marrow 92
Lung 11
Liver 2
Pleura 1
Multiple organs 12
Nodal disease 35 (22.0)
Normal sized nodes that were FDG avid
below the diaphragm
20
Normal sized nodes that were FDG avid
above the diaphragm
7
Splenic FDG avid foci 7
Both of the above 1
Difference in opinion 6 (3.8)
Imaging findings interpreted differently by the
local radiologist and the core laboratory
PET CT reader or the treating clinician
6
Downstaging by PET-CT due to N (% of downstaged patients)
Extranodal disease 25 (33.8)
Lung 11
Bone marrow 5
Pleura 3
Bone 1
Adrenal gland 1
Liver 2
Small bowel 1
Multiple organs 1
Nodal disease 34 (45.9)
Enlarged nodes that were not FDG avid below
the diaphragm
21
Enlarged nodes that were not FDG avid above
the diaphragm
1
Splenomegaly on CT, normal FDG uptake 8
Splenic lesion/s on ceCT not FDG avid 3
Splenomegaly on CT & enlarged nodes not
FDG avid
1
Difference in opinion 15 (20.3)
Imaging findings interpreted differently by the
local radiologist and the core laboratory PET
CT reader or the local radiologist and the
treating clinician
15
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nodal involvement also occurred, mostly below the diaphragm
(Table 2). Reasons for downstaging included enlarged nodes and/or
spleen, which were not FDG-avid and extranodal sites with abnormal
morphology but no FDG uptake (Table 2).
The PET2 scans of patients with discrepant staging ﬁndings were
compared with the PET0 scan (supplemental Table 1, available on the
Blood Web site). At PET2, FDG uptake at sites that resulted in
upstaging decreased in parallel with other sites of disease during
treatment in all cases (supplemental Table 1). Twenty patients had
extranodal lesions on CT that were not FDG-avid. Five of these 20
patients had lesions that did not change on treatment (Figure 3) and
were considered unlikely to represent lymphoma (1 adrenal adenoma,
3 lungnodule/s, 1 bone lesion).Onepatient hada37-mmcavitating lung
nodule on CT, which enlarged from 5-mm 7 days prior on PET-CT and
was probably inﬂammatory. Six patients had indeterminate lung
nodules, and 1 patient had lobar consolidation that all resolved; 3
patients had pleural effusions that resolved; in all these cases, the
changes may have been reactive, inﬂammatory, or related to
lymphoma. There were 4 patients, small bowel (1), liver lesions (2),
and 1 patientwith bowel and liver lesions,where ceCTwas considered
more likely to indicate the correct stage. Three patients had splenic
lesions on ceCT not seen on PET. Bone marrow involvement was
missed on PET-CT but identiﬁed on biopsy in 5 patients.
There were 21 cases where review of the reports suggested that the
same imaging ﬁndings had been differently interpreted by the local
radiologist and the core laboratory PET CT reader or the local
radiologist and the treating clinician (Table 2).
Reporting of early response assessment
A total of 1123 PET2 scans were assessable in the trial (Figure 1); 223
PET2 scans were performed in the PET center of one of the core
laboratories (Figure 1). Local readers scored 300 of the remaining 900
scans (33%). One hundred forty PET2 scans were scored by all readers
at the 5 core laboratories.
When the liver threshold was used, there was agreement between
core laboratories that a scan was negative (score 1-3) or positive
(score 4 or 5) in 122 of 140 scans: k (95% conﬁdence interval [CI]),
0.84 (0.76-0.91), indicating very good agreement. Therewas agree-
ment between central and local readers in 276 of 300 scans;
k (95% CI): 0.77 (0.68-0.86; Table 3), indicating good agreement.
When the mediastinal threshold was used, there was agreement
between core laboratories that a scan was negative (score 1 or 2) or
positive (scores 3-5) in 81 of 140 scans: k (95% CI), 0.58 (0.50-0.66),
indicating moderate agreement. There was agreement between central
and local readers in 249 of 305 scans: k (95% CI), 0.64 (0.55-0.73;
Table 4), indicating good agreement.
Identical scores ranging from 1 to 5 were given in 169 of 300 PET2
scans by central and local readers (Table 5). When assigning scans as
positive or negative, 15 PET2 scans scored by local readers as positive
were deemed negative by central review, whereas 9 PET2 scans scored
by local readers as negative were deemed positive by central review
using the liver threshold that determined treatment.
One hundred sixty one PET3 scans were performed; 26 were
performed at the PET center of one of the core laboratories (Figure 1).
Local readers scored 47 of the remaining PET3 scans (36%). Using the
liver threshold, there was agreement among central and local readers
that a scan was negative or positive in 45 of 47 scans: k (95% CI),
0.91 (0.78-1.00), indicating very good agreement. For the mediastinal
threshold, there was agreement in 39 of 47 scans: k (95% CI),
0.61 (0.45-0.87), indicating good agreement.
Identical scores ranging from 1 to 5 were given in 24 of 47 PET3
scans by central and local readers using the liver threshold.
Figure 2. Example of upstaging by PET-CT. (A) CT
and (B) PET coronal images show a case upstaged by
PET-CT. Nodal and splenic involvement was reported
on CT and interpreted as stage 3. The PET scan
showed multifocal uptake in bone marrow upstaging to
stage 4.
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Discussion
Our study is the ﬁrst to compare PET-CT staging with the
established standard of clinical assessment, contrast-enhanced CT,
and bone marrow biopsy stage in a large cohort of patients with
advanced HL in an international trial. PET-CT altered staging in
20% of patients compared with the standard approach, which is
at variance with earlier reports that suggested stage change oc-
curred more often in patients with early stage rather than advanced
disease.10,20 Upstaging occurred more frequently than downstaging,
with extranodal disease accounting for 74% of the upstaged scans,
mostlydue toan increased sensitivity ofPETfordetectingbonemarrow
involvement.
Baseline and response scans were compared, and the ﬁndings were
correlated with other imaging, where available, to determine the
etiology of lesions that accounted for the discrepancy in stage. This
supported the notion that PET-CT stage ismore accurate thanCT in the
majority of cases. There were only 4 patients with organ involvement
and 3 with probable splenic involvement identiﬁed on ceCT that were
missed on PET-CT. Bone marrow biopsy identiﬁed involvement in
5 cases (0.4%), where there was a normal marrow appearance on
Figure 3. Example of downstaging by PET-CT. (Left)
CT and (right) PET axial images show a case down-
staged by PET-CT. (A) There was nodal disease in the
mediastinum and a 22-mm lung nodule in the left lung
(arrow), reported on CT as stage 4. The PET scan
showed high uptake in lymph nodes but no FDG uptake
in the lung nodule, suggesting the nodule was unlikely
to be due to lymphoma interpreted as stage 2. (B) After
treatment, there was resolution of uptake in lymph
nodes but the lung nodule (arrow) was unchanged.
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PET-CT conﬁrming that routine bone marrow biopsy is no longer
required.7,31
We cannot determine whether staging by PET-CT impacted
management because patients were registered in the trial based on
having at least stage IIA disease with adverse risk factors on other
imaging and marrow biopsy. Upstaging by PET-CT would have been
unlikely to impactmanagement as patients had alreadybeen assessed as
requiring full-course chemotherapy. Similarly, downstaging fromstage
4 to stage 3 would not have impacted treatment. PET-CT, however,
downstaged 56 patients to stage 2 and 1 patient to stage 1 (5% of the
study population), and this could potentially inﬂuence treatment
choices.
Our results are in keeping with earlier reports11,13-16 that PET
stages HL patients differently to ceCT in;15% to 30% of cases. Early
reports had fewer patients, were retrospective, and were published
prior to thewidespread introduction of PET-CT.11-16More recently,
Hutchings et al3 compared PET with CT staging prospectively in
99 patients with HL (61 with PET-CT), and Rigacci et al10 in
186 patients (56 with PET-CT). Upstaging, especially by identiﬁca-
tion of extranodal sites, occurred more frequently than downstaging,
similar to ourﬁndings.3 Lesionswere also overlooked onCT andmore
easily identiﬁed on PET.3,10,20
The truth as to whether lesions identiﬁed only on PET represent
lymphoma is difﬁcult to determine as biopsy of discrepant lesions is
rarely performed. Correlative imaging, treatment response, follow-up,
biopsy, or a combination usually serves as a reference standard.3,10-14
Young et al,32 in 49 HL patients, veriﬁed stage by laparotomy in 11
patients and biopsy of discordant lesions in the remainder. PET stage
was correct in 26 upstaged patients, and a single patient down-
staged compared with CT. Taken together, these studies demon-
strated improved sensitivity and similar speciﬁcity using PET compared
with CT.
Changes in management were reported in 12 of 186 patients by
Rigacci et al.10 Ten patients were upstaged from limited to
advanced disease, and 2 patients had an increase in the radiotherapy
ﬁeld using PET. Hutchings et al3 reported that 7 patients upstaged
by PET to advanced disease were treated for limited disease, but
only 1 patient developed progressive lymphoma. Eighteen patients
had disease progression overall, suggesting that understaging by
CT probably did not adversely impact on outcome. The same group
later reported, however, that the routine use of PET-CT in their
clinical practice resulted in stage migration, with a higher risk of
progression associated with focal FDG-avid skeletal lesions.33
Bone marrow involvement was the most common reason for discrep-
ancy in stage between PET and CT in our series. Munker et al13 also
reported signiﬁcantlymore treatment failures amongpatients staged as
I or II on CT, yet III or IV on PET compared with patients who were
stage I or II by both CT and PET.More accurate delineation of disease
is thus likely to be of beneﬁt for patient management and for radiation
planning10,15.
International guidelines have recommended that PET-CT
should be used for staging of FDG-avid lymphomas,7 because it
is more accurate than CT and because a staging scan improves the
accuracy of response assessment.6 The role of ceCT in staging is
still debated, although the international guidelines concluded that
ceCT had limited application7 as it rarely altered staging or
management.8,9 Our study conﬁrms this conclusion; organ in-
volvement was detected on ceCT but not PET-CT in 4 patients and
splenic lesions in 3 patients, leading to stage change. On the other
hand, PET-CT detected extranodal disease in 118 patients and
splenic FDG-avid foci in 7 patients and stage was changed. Further,
the effective dose associated with ceCT is ;16 mSv, which is
similar to the combined dose from PET with lower-dose un-
enhanced CT. Avoiding ceCT for staging would thus reduce a pa-
tient’s radiation dose by 50%. Although ceCT may be required for
planning radiotherapy, in our study, ,10% of patients required
this.7
PET-CT is recommended for response assessment in FDG-
avid lymphomas using the 5-PS.34 The 5-PS has good inter-
observer agreement22,24,25,35-37 and is predictive of patient
outcomes,29,35,38-40 especially in advanced HL.37,41 An advantage
of the 5-PS is that the threshold used to deﬁne complete metabolic
response can be altered according to the clinical context or research
question.34 In the RATHL designwhere patients with a positive scan
received escalation from ABVD to BEACOPP, investigators
preferred to use the liver threshold to avoid the risk of overtreating
patients. In some trials designed to explore de-escalation strategies, a
lower mediastinal threshold has been used to avoid the risk of
undertreating patients.1,28,29 Yahalom42 expressed concern that the
good agreement reported among expert readers may not be
reproducible in the community setting, in particular, if treatment
was adapted on the basis of the result. Our study demonstrated
similar levels of agreement among experts and local readers, with
good or very good agreement for the liver but lowermoderate to good
agreement for themediastinal threshold. In RATHL, the outcome for
patientswith a negative scanwas not inﬂuenced by the PET2 score,43
and our observations suggest that the liver is likely to be a more
reproducible threshold, although readers may possibly have paid
closer attention to the decision to assign a score of 4 rather than 3,
knowing this would result in treatment escalation. The better
agreement using the liver43 may be explained by the higher uptake in
liver than mediastinum, so the contrast between lesions with low-
grade uptake and the reference region is easier to appreciate.22,23
In addition, there is more uniform uptake in the liver than the
mediastinumwhere uptake can be heterogeneous with focal uptake
in the vessel wall. Standardization of patient preparation and
scanning are important to ensure homogenous uptake in the liver.44
The agreement for scoring at PET3was good,which has not previously
been reported, although the numbers assessed were small. This is
reassuring as BEACOPP chemotherapy can be associated with
diffuse bonemarrow uptake, whichmight havemade interpretation
more challenging.
The main limitations to our study were that it was not possible
for ceCT scans to be re-reviewed alongside PET-CT scans, and we
could not measure the impact of PET-CT on management. Bias
may have occurred in the scoring of response scans by local readers
Table 3. Agreement between central and local readers at PET2
using liver threshold
Local
Central
Positive Negative
Positive 54 15
Negative 9 222
Table 4. Agreement between central and local readers at PET2
using mediastinal threshold
Local
Central
Positive Negative
Positive 85 12
Negative 39 164
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as it was optional to score scans, although readers were evenly split
between academic and nonacademic institutions.
In conclusion, staging of HL patients in this large prospective
study conﬁrms that an important proportion will be staged
differently using PET-CT compared with clinical assess-
ment, CT, and bone marrow biopsy. When discordance occurs
in the imaging stage, PET-CT is usually more accurate than
CT, which may impact on management.3,10,14,32 These ﬁndings
support the move to a modern standard using PET-CT for stag-
ing and suggests that, in the vast majority of cases, ceCT is not
required.6,7
Good agreement between local and expert readers indicates that the
5-PS is robust for assessing responsewhen standardized PET protocols
are used, and it works effectively in the community setting and in
clinical trials. The ﬁnal results of the RATHL trial will determine
whether response adaptation using the 5-PS is successful at improving
outcomes in advanced HL. In the meantime, our results strengthen the
application of the 5-PS as the optimal method for response assessment
in HL.
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